- Associated Press•3 months ago
On a per-share basis, the South San Francisco, California-based company said it had a loss of 42 cents. The biopharmaceutical company posted revenue of $109,000 in the period. The company's shares closed ...
- Zacks•2 years ago
Targacept, Inc. announced disappointing top-line data from a phase I/II exploratory study on its candidate TC-6499 for the treatment of diabetic gastroparesis.
NasdaqGS . Currency in USD
|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52wk Range||undefined - undefined|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||N/A|
|Dividend & Yield||N/A (N/A)|